5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy

References

• The Danish Cancer Society. Report: Kræft i Danmark. The Danish Cancer Society; 2022. Available from: http://www.cancer.dk.
   Google Scholar
• DLCG/DOLG. Annual report of lung cancer in the Danish population 2021 (DLCG. Årsrapport 2021); 2022. Available from: http://www.lungecancer.dk/Lungecancer_-aarsrapport-2021offentlig.pdf.
   Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. doi: 10.1056/NEJMoa011954.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551. doi: 10.1200/JCO.2007.15.0375.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314. doi: 10.1002/cncr.28509.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AH, Krapcho M, et al. SEER cancer statistics review, 1975–2018. Bethesda, MD: National Cancer Institute; 2021. Available from: https://seer.cancer.gov/csr/1975_2018/
   Google Scholar
• The Danish Medicines Council. [Ikke-småcellet lungekræft - 1. linje (medicinraadet.dk)]. [cited 2023 May]. Danish. Available from: https://medicinraadet.dk/anbefalinger-og-vejledninger/.
   Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi: 10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi: 10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi: 10.1056/NEJMoa1709937.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi: 10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi: 10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi: 10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50. J Clin Oncol. 2021;39(21):2339–2349. doi: 10.1200/JCO.21.00174.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials Checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733. doi: 10.1200/JCO.20.01605.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol. 2017;18(12):1600–1609. doi: 10.1016/S1470-2045(17)30690-3.
   PubMed Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195. doi: 10.1016/j.lungcan.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Mouritzen MT, Carus A, Ladekarl M, et al. Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced NSCLC-real world efficacy. Cancers. 2021;13(19):4846. doi: 10.3390/cancers13194846.
   PubMed Web of Science ®Google Scholar
• Mouritzen MT, Junker KF, Carus A, et al. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta Oncol. 2022;61(4):409–416.
   PubMed Web of Science ®Google Scholar
• Kari Chansky MS, Nicholson AG, Rusch V, IASLC Staging and Prognostic Factors Committee AB, and Participating Institutions, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109–1121. doi: 10.1016/j.jtho.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Brierley JG, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. John Wiley & Sons, Inc; 2017.
   Google Scholar
• Bjørnhart B, Hansen KH, Jørgensen TL, et al. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953–961. doi: 10.1080/0284186X.2019.1615636.
   PubMed Web of Science ®Google Scholar
• World Health organization. World Medical Association declaration of Helsinki. Ethical principles for medical research involving human subjects. Bullet World Health Org. 2001;79:373–374. https://apps.who.int/iris/handle/10665/268312.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
   PubMed Web of Science ®Google Scholar
• Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40(6):586–597. doi: 10.1200/JCO.21.01497.
   PubMed Web of Science ®Google Scholar
• StataCorp LLC. Stata statistical software: release 17. 17.0 Edition. College Station, TX: statacorp LLC; 2021.
   Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–137. doi: 10.1200/JCO.21.02229.
   PubMed Web of Science ®Google Scholar
• Lee SM, Prabhash K, Han B, et al. LBA11 – IPSOS: results from a phase III study of first-line (1L) atezolizumab (atezo) vs. single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Ann Oncol. 2022;33:S1418–S1419. doi: 10.1016/j.annonc.2022.08.052.
   Web of Science ®Google Scholar